Modulation of plasma fibrinogen levels by ticlopidine in healthy volunteers and patients with stable angina pectoris

Thrombosis and Haemostasis

Volumn 76, Issue 2, 1996, Pages 166-170

  De Moat, Moniek P M ^a,b   Arnold, Alf E R ^c   Van Buuren, Stef ^b   Paul Wilson, J H ^a   Kluft, Cornelis ^b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b TNO   (Netherlands)

^c Alkmaar and Dutch Network for Cardiovascular Research   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRIN; FIBRINOGEN; TICLOPIDINE;

ACUTE PHASE RESPONSE; ADULT; AGED; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOGEN METABOLISM; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT;

EID: 0029841821     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650547     Document Type: Article

References (56)

1. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thrompson SG. Haemostatic function and ischaemic heart disease: principle results of the Northwick Part heart study. Lancet 1986; ii: 533-7.
2. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-5.
3. Stone MC, Thorpe JM. Plasma fibrinogen - a major coronary risk factor. J Roy Coll Gen Pract 1985; 35: 565-9.
4. Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insight from the Framingham study. Am Heart J 1987; 113: 1006-10.
5. Balleisen L, Schulte H, Assmann G, Epping PH, van de Loo J, Coagulation factors and the progress of coronary heart disease (Letter). Lancet 1987; i: 461.
6. Kostis JB, Baughman J, Kuo PT. Association of recurrent myocardial infarction with hemostatic factors: a prospective study. Chest 1982; 81: 571-5.
7. Haverkate F. Thrombosis and disabilities. In: Advances in Medical Biology. C Baya, ed. 1994, vol 3, IOS Press, Amsterdam, pp 81-103.
8. Baxter K, Wiseman S, Powell J, Greenhalgh R. Pilot study of a screening test for peripheral arterial disease in middle aged men: fibrinogen as a possible risk factor. Cardiovasc Res 1988; 22: 300-2.
9. Resch KL, Ernst E, Matrai A, Paulsen HF. Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors. Ann Intern Med 1988; 19: 634-6.
10. Small M, Lowe GDO, Beattie JM. Severity of coronary artery disease and basal fibrinolysis. Haemostasis 1987; 17: 305-11.
11. Lowe GDO, Drummond MM, Lorimer AR, Hutton I, Forbes CD, Prentice CRM, Barbenel JC. Relation between extent of coronary artery disease and blood viscosity. Br Med J 1980; 80: 673-7.
12. Handa K, Kono S, Saku K, Sasaki J, Kawano T, Sasaki Y, Hiroki T, Arakawa K. Plasma fibrinogen levels as an independent indicator of severity of coronary atherosclerosis. Atherosclerosis 1989; 77: 209-13.
13. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
14. Broadhurst P, Kelleher C, Hughes L, Imeson JD, Raftery EB. Fibrinogen, factor VII clotting activity and coronary artery disease severity. Atherosclerosis 1990; 85: 169-73.
15. ECAT Angina Pectoris Study Group. ECAT Angina Pectoris Study: base- line associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993; 14: 8-17.
16. de Maat MPM, Pietersma A, Kofflard M, Sluiter W, Kluft C. Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. Atherosclerosis 1996; 121: 185-91.
17. Neumann V, Cove DH, Shapiro LM, George AJ, Kenny MW, Meakin M, Stuart J. Effect of ticlopidine on platelet function and blood rheology in diabetes mellitus. Clin Hemorr 1983; 3: 13-21.
18. Conard J, Lecrubier C, Scarabin PY, Horellou MH, Samama M, Bousser MG. Effects of long term administration of ticlopidine on platelet function and hemostatic variables. Thromb Res 1980; 20: 143-8.
19. Randi ML, Fabris F, Crociani ME, Battocchio F, Girolami A. Effects of ticlopidine on blood fibrinogen and blood viscosity in peripheral atherosclerotic disease. Drug Res 1985; 12: 1847-9.
20. Randi ML, Mares M, Fabris F, Tison T, Barbbone E, Girolami A. Decrease of fibrinogen in patients with peripheral atherosclerotic disease by Ticlopidine. Arzneim-Forsch/Drug. Res 1991; 41 (I): 414-6.
21. Palareti G, Poggi M, Torricelli P, Balestra V, Coccheri S. Long-term effects of ticlopidine on fibrinogen and haemorheology in patients with peripheral arterial disease. Thromb Res 1988; 52: 621-9.
22. Tekeres M, Sarosi I, Juricskay I, Losoncsy H, Nagy I. Effect of longterm ticlopidine therapy on the rheological properties of blood. Seventh International Congress on Thrombosis, Valencia, Spain, October 1982, (abstract 215).
23. Vicari AM, Penasa L, Pozza G. Clinical effectiveness of tidopidine in diabetic subjects: a double-blind study. Haemostasis 1982; 12: 203 (Abstract).
24. Aukland A, Hurlow RA, George AJ, Stuart J. Platelet inhibition with ticlopidine in atherosclerotic intermittent claudation. J Clin Pathol 1982; 35: 740-3.
25. Drouet L, Mazoyer E, Ripoll L, Dosquet C, Tobelem G. Fibrinogen pheno- type (plasma level and activity) and genotype in atherothrombotic patients. Evolution after ticlopidine treatment. Thromb Haemost 1995; 76: 1379 (Abs 1834).
26. Defreyn G, Bernat A, Delebassee D, Maffrand J. Pharmacology of Ticlopidine: A Review. Sem Thromb Hemost 1989; 15: 159-66.
27. O'Brien JR. Ticlopidine - a promise for the prevention and treatment of thrombosis and its complications. Haemostasis 1983; 13: 1-54.
28. O'Brien JR, Etherington MD, Shuttleworth RD. Ticlopidine- an antiplatelet drug: Effects in human volunteers. Thromb Res 1978; 13: 245-54.
29. Hass WK, Easton JD, Adams HP Jr, Molony BA, Kamm B. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501-7.
30. Stuart J. The acute-phase reaction and haematological stress syndrome in vascular disease. Int J Microcirc: Clin Exp 1984; 3: 115-29.
31. Clinton SK, Libby P. Cytokines and growth factors in atherogenesis. Arch Pathol Lab Med 1992; 116: 12292-3000.
32. Entman ML, Michael L, Rossen RD, Dreyer WJ, Anderson DC, Taylor AA, Smith CW. Inflammation in the course of early myocardial ischemia. FASEB J 1991; 5: 2529-37.
33. La Duca FM, Tinsley LA, Dang CV, Bell WR. Stimulation of fibrinogen synthesis in cultured rat hepatocytes by fibrinogen degradation product fragment D. Proc Natl Acad Sci USA 1989; 86: 8788-92.
34. Peerschke EIB. The platelet fibrinogen receptor. Sem Haem 1985; 23: 241-59.
35. Kessler CM, Bell WR. The effect of homologous thrombin and fibrinogen degradation products on fibrinogen synthesis in rabbits. J Lab Clin Med 1979; 93: 768-82.
36. Princen HMG, Moshage HJ, Emeis JJ, de Haard HJW, Nieuwenhuizen W, Yap SH. Fibrinogen fragments X, Y, D and E increase levels of plasma fibrinogen and liver mRNA's coding for fibrinogen polypeptides in rats. Thromb Haemost 1985; 53: 212-5.
37. Moshage HJ, Princen HMG, van Pelt J, Roelofs HMJ, Nieuwenhuizen W, Yap SH. Differential effects of endotoxin and fibrinogen degradation products (FDPS) on liver synthesis of fibrinogen and albumin: evidence for the involvement of a novel monokine in the stimulation of fibrinogen synthesis induced by FDPS. Int J Biochem 1990; 22: 1393-400.
38. Von Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogenes. Acta Haematol 1957; 17: 237-46.
39. Humphries SE, Cook M, Dubowitz M, Stirling Y, Meade TW. Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet 1987; 1: 1452-5
40. Cook M, Godiner N, Green F, Stirling Y, Meade TW, Humphries SE. Genetic control of plasma fibrinogen levels. In: Fibrinogen 3. Biochemistry, biological functions, gene regulation and expression. Mossewson MW.
41. Berg K, Kierulf P. DNA polymorphisms at fibrinogen loci and plasma fibrinogen concentration. Clin Gen 1989; 36: 229-35.
42. Thomas AE, Green FR, Kelleher CH, Wilkes HC, Brennan PJ, Meade TW, Humphries SE. Variation in the promoter region of the β fibrinogen gene is associated with plasma fibrinogen levels in smokers and non-smokers. Thromb Haemost 1991; 65: 487-90.
43. Green F, Hamsten A, Blombäck M, Humphries S. The role of β-fibrinogen genotype in determining plasma fibrinogen levels in young survivors of myocardial infarction and healthy controls from Sweden. Haemostasis 1993; 70: 915-20.
44. Sherman LA, Catabolism of fibrinogen and its derivatives. Thromb Haemost 1977; 38: 809-22.
45. Hoegee-de Nobel E, Voskuilen M, Briët E, Brommer EJP, Nieuwenhuizen W. A monoclonal antibody-based quantitative enzyme immuoassay for the determination of plasma fibrinogen concentrations. Thromb Haemost 1988; 60: 415-8.
46. Koopman J, Haverkate F, Koppert P, Nieuwenhuizen W, Brommer EJP, van der Werf WGC. New enzyme immuno assay of fibrin-fibrinogen degradation products in plasma using a monoclonal antibody. J Lab Clin Med 1987; 109: 75-84.
47. Koppert PW, Hoegee-De Nobel E, Nieuwenhuizen W. A monoclonal antibody -based immunoassay for fibrin degradation products in plasma. Thromb Haemost 1988; 59: 310-5.
48. Koopman J, Haverkate F, Koppert P, Nieuwenhuizen W, Brommer EJP, van der Werf WGC. New enzyme immuno assay of fibrin-fibrinogen degradation products in plasma using a monoclonal antibody. J Lab Clin Med 1987; 109: 75-84.
49. +1689 (AvaII), and BclI (β-fibrinogen) and TaqI (α-fibrinogen), and their detection by PCR. Human Mutation 1994; 3: 79-81.
50. Senn S. Cross-over trials in clinical research. Barnet V (Ed), 1993, John Wiley & Sons Chichester, Amram DL, Siebenlist KR, DiOrio JP (eds), 1988, Elsevier Science Publishers BV, Amsterdam, 1 pp 1-15.
51. Harbison JW. For the Ticlopidine Aspirin Stroke Study Group. Ticlopidine versus aspirin for the prevention of recurrent stroke. Stroke 1992; 23: 1723-7.
52. Krusius T, Hirvonen M, Vahtera E, Kala R. Short-term aspirin treatment does not reduce plasma fibrinogen concentration in young healthy adults. Thromb Res 1994; 75: 653-6.
53. Hampton KK, Cerletti C, Louizou LA, Bucchi F, Donati MB, Davies JA, de Gaetano G, Prentice CRM. Coagulation, fibrinolytic and platelet function in patients on long-term therapy with aspirin 300 mg or 1,200 mg daily compaired with placebo. Thromb Haemost 1990; 64: 17-20.
54. Eritsland J, Seljeflot I, Arnesen H, Smith P, Westvik A. Effects of long- term treatment with warfarin on fibrinogen, FPA, TAT, and D-Dimer in patients with coronary artery disease. Thromb Res 1992; 66: 55-60.
55. de Bart ACW, Hennis BC, Havelaar AC, Kluft C. Variability in information from a single venapuncture in healthy volunteers: analysis of the haemostatic variables fibrinogen, plasminogen activator inhibitor (PAI) activity and histidine-rich glycoprotein (HRG). Fibrinolysis 1992; 6, suppl 3: 81-2.
56. Scarabin P, Plu-Bureau G, Bara L, Bonithon-Kopp C, Guize L, Samama MM. Haemostatic variables and menopausal status: influence of hormone replacement therapy. Thromb Haemost 1993; 70: 584-7.